Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients

Who May Qualify: - Written willing to sign a consent form for the prospective cohort - Histopathological diagnosis of high-risk soft tissue sarcoma and one of the following subtypes: DDLPS, LMS, SS, vascular sarcomas or MPNST. Other subtypes may be included with PI approval. - High-risk sarcoma definition: - Greater than 5cm or Grade 3 - Deep anatomic location - Have disease amenable to biopsy o Patients who are not amenable to repeat biopsy at baseline can be reviewed with the local site PI for consideration of inclusion to the study - Resectable tumour - Measurable disease by RECIST 1.1 - Aged ≥ 18 years - WHO performance status 0-2 - For patients receiving NCT, medically fit enough, with your organs (liver, kidneys, etc.) are working well enough based on blood tests, to undergo neoadjuvant chemotherapy - Patients medically fit enough to undergo surgical resection - Capable of giving written willing to sign a consent form (for prospective cohort) and comply with the study schedule - Patients may also participate in the STRASS 2 trial Who Should NOT Join This Trial: -Prior invasive malignancy in last 5 years, low risk malignancies in the last 5 years may be reviewed by the PI. - Known additional malignancy that is progressing or requires active treatment - Metastatic disease not amenable to curative intent local therapy - Any active uncontrolled medical conditions Always talk to your doctor about whether this trial is right for you.